The mutation accounts for 25% of all non-small cell lung cancers.

Takeaway

• On December 12, 2022, the US Food and Drug Administration (FDA) granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics, Inc.) for adult patients with locally advanced or metastatic NSCLC caused by a glycine-to-cysteine mutation at codon 12 of the ...